- Home
- BTAI vs SBFM Comparison
BTAI vs SBFM Comparison
Compare BTAI & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- SBFM
- Stock Information
- Founded
- BTAI 2017
- SBFM 2006
- Country
- BTAI United States
- SBFM United States
- Employees
- BTAI N/A
- SBFM N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- SBFM Health Care
- Exchange
- BTAI Nasdaq
- SBFM Nasdaq
- Market Cap
- BTAI 8.3M
- SBFM 6.7M
- IPO Year
- BTAI 2018
- SBFM N/A
- Fundamental
- Price
- BTAI $1.81
- SBFM $1.57
- Analyst Decision
- BTAI Buy
- SBFM Strong Buy
- Analyst Count
- BTAI 5
- SBFM 1
- Target Price
- BTAI $34.80
- SBFM $15.00
- AVG Volume (30 Days)
- BTAI 325.6K
- SBFM 196.4K
- Earning Date
- BTAI 08-05-2025
- SBFM 08-15-2025
- Dividend Yield
- BTAI N/A
- SBFM N/A
- EPS Growth
- BTAI N/A
- SBFM N/A
- EPS
- BTAI N/A
- SBFM N/A
- Revenue
- BTAI $1,852,000.00
- SBFM $36,234,578.00
- Revenue This Year
- BTAI N/A
- SBFM $32.20
- Revenue Next Year
- BTAI $362.49
- SBFM $32.74
- P/E Ratio
- BTAI N/A
- SBFM N/A
- Revenue Growth
- BTAI 5.47
- SBFM 35.51
- 52 Week Low
- BTAI $1.17
- SBFM $1.17
- 52 Week High
- BTAI $19.84
- SBFM $6.19
- Technical
- Relative Strength Index (RSI)
- BTAI 48.12
- SBFM 53.18
- Support Level
- BTAI $1.70
- SBFM $1.51
- Resistance Level
- BTAI $2.00
- SBFM $1.61
- Average True Range (ATR)
- BTAI 0.15
- SBFM 0.08
- MACD
- BTAI -0.03
- SBFM 0.00
- Stochastic Oscillator
- BTAI 20.00
- SBFM 78.48
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.